Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors
Adlai Nortye Group (ANL) partners with Eli Lilly (LLY) and Merck KGaA (MKKGY) to evaluate AN4035 in combination with cetuximab for solid tumors. The Phase I trial will assess safety and efficacy, with Lilly and Merck supplying the drug. ANL's stock closed at $10.88, up 3.40% in pre-market trading.
How this was made
The 30-second read
Why it matters
The collaboration validates the platform and may attract further partnership interest, but the true catalyst will be clinical data read‑outs.
Market read
First‑report of a multi‑partner Phase I study in RAS‑driven solid tumors; likely short‑term boost for ANL, neutral for partners.
What to watch
The trial's staggered start and lack of disclosed financial terms limit immediate upside.
Background
Adlai Nortye Group is a micro‑cap biotech developing antibody‑drug conjugates. The AN4035 ADC targets CEACAM5 and delivers a pan‑RAS inhibitor.
Ticker impact
Adlai Nortye Group announced a new clinical‑trial collaboration with Eli Lilly and Merck KGaA to test its ADC AN4035 in solid tumors.
likely upward pressure as investors price in the collaboration and potential future data read‑outs
First‑report of a multi‑partner Phase I study; small‑cap biotech typically reacts positively to such validation.
Eli Lilly will supply cetuximab at no cost for U.S. sites in the ANL trial, expanding its oncology portfolio.
minimal impact; market already expects ongoing collaborations
The deal is a supply agreement without financial commitment, typical for large pharma.
Market effects
Highlights growing interest in ADCs targeting RAS‑driven cancers, potentially benefiting peers in oncology biotech.
May draw attention to U.S., Australian and Chinese oncology trial sites.
Adds to the pipeline momentum for ADC technologies worldwide.
Counterpoint
If early‑stage data disappoint, the collaboration could become a liability for ANL, weighing on its valuation.
Key entities
- companyAdlai Nortye Group
Developer of AN4035 ADC
- companyEli Lilly and Company
Supplier of cetuximab for U.S. trial sites
- companyMerck KGaA
Supplier of cetuximab for Australian and Chinese sites
